Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice
- PMID: 23896226
- DOI: 10.1016/j.yjmcc.2013.07.011
Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice
Abstract
Myosin-binding protein C (Mybpc3)-targeted knock-in mice (KI) recapitulate typical aspects of human hypertrophic cardiomyopathy. We evaluated whether these functional alterations can be reproduced in engineered heart tissue (EHT) and yield novel mechanistic information on the function of cMyBP-C. EHTs were generated from cardiac cells of neonatal KI, heterozygous (HET) or wild-type controls (WT) and developed without apparent morphological differences. KI had 70% and HET 20% lower total cMyBP-C levels than WT, accompanied by elevated fetal gene expression. Under standard culture conditions and spontaneous beating, KI EHTs showed more frequent burst beating than WT and occasional tetanic contractions (14/96). Under electrical stimulation (6Hz, 37°C) KI EHTs exhibited shorter contraction and relaxation times and a twofold higher sensitivity to external [Ca(2+)]. Accordingly, the sensitivity to verapamil was 4-fold lower and the response to isoprenaline or the Ca(2+) sensitizer EMD 57033 2- to 4-fold smaller. The loss of EMD effect was verified in 6-week-old KI mice in vivo. HET EHTs were apparently normal under basal conditions, but showed similarly altered contractile responses to [Ca(2+)], verapamil, isoprenaline and EMD. In contrast, drug-induced changes in intracellular Ca(2+) transients (Fura-2) were essentially normal. In conclusion, the present findings in auxotonically contracting EHTs support the idea that cMyBP-C's normal role is to suppress force generation at low intracellular Ca(2+) and stabilize the power-stroke step of the cross bridge cycle. Pharmacological testing in EHT unmasked a disease phenotype in HET. The altered drug response may be clinically relevant.
Keywords: ATPase, Ca(2+) transporting, cardiac mRNA; Acta1; Alpha skeletal actin protein; Atp2a2; BPM; Beats per minute; Cardiac myosin-binding protein C; Cardiac myosin-binding protein C (cMyBP-C); Contraction time (spontaneous beating); Diastolic left ventricular internal diameter; Disease modeling; EC(50); EHT; EMD; EMD 57033; Engineered heart tissue; Engineered heart tissue (EHT); HCM; HET; Half maximal effective concentration; Half maximal inhibitory concentration; Heterozygous Mybpc3-targeted knock-in mice; Homozygous Mybpc3-targeted knock-in mice; Human cardiac myosin-binding protein C gene; Hypertrophic cardiomyopathy; IC(50); ISO; Induced pluripotent stem cells; Isoprenaline; KI; LVIDd; LVIDs; LVMBW; Left ventricular mass/body weight ratio; MYBPC3; Mouse cardiac myosin-binding protein C gene or mRNA; Mybpc3; Myh6; Myh7; Myofilament Ca(2+) sensitivity; Relaxation time (spontaneous beating); Slc8a1; Sodium calcium exchanger; Systolic left ventricular internal diameter; T1; T2; TTP; TTP50; TTR50; TTR90; Time to 100% of maximal twitch force; Time to 50% of maximal twitch force; Time to 50% of relaxation; Time to 90% of relaxation; cMyBP-C; iPSC; α-myosin heavy chain, α-MHC gene or mRNA; α-skAct; α-skeletal actin gene or mRNA; β-myosin heavy chain, β-MHC gene or mRNA.
© 2013. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.J Mol Cell Cardiol. 2016 Aug;97:82-92. doi: 10.1016/j.yjmcc.2016.03.003. Epub 2016 Apr 22. J Mol Cell Cardiol. 2016. PMID: 27108529
-
Translational investigation of electrophysiology in hypertrophic cardiomyopathy.J Mol Cell Cardiol. 2021 Aug;157:77-89. doi: 10.1016/j.yjmcc.2021.04.009. Epub 2021 May 3. J Mol Cell Cardiol. 2021. PMID: 33957110 Free PMC article.
-
Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.Sci Rep. 2019 Dec 3;9(1):18152. doi: 10.1038/s41598-019-54665-2. Sci Rep. 2019. PMID: 31796859 Free PMC article.
-
Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structure-function relationships.Pflugers Arch. 2014 Feb;466(2):201-6. doi: 10.1007/s00424-013-1400-3. Epub 2013 Nov 17. Pflugers Arch. 2014. PMID: 24240729 Review.
-
The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.FEBS Lett. 2022 Mar;596(6):703-746. doi: 10.1002/1873-3468.14301. Epub 2022 Feb 28. FEBS Lett. 2022. PMID: 35224729 Review.
Cited by
-
Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy.Circ Genom Precis Med. 2020 Oct;13(5):396-405. doi: 10.1161/CIRCGEN.120.002929. Epub 2020 Aug 25. Circ Genom Precis Med. 2020. PMID: 32841044 Free PMC article.
-
Research priorities in sarcomeric cardiomyopathies.Cardiovasc Res. 2015 Apr 1;105(4):449-56. doi: 10.1093/cvr/cvv019. Epub 2015 Jan 28. Cardiovasc Res. 2015. PMID: 25631582 Free PMC article. Review.
-
Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function.Cell Rep. 2015 Oct 27;13(4):733-745. doi: 10.1016/j.celrep.2015.09.025. Epub 2015 Oct 17. Cell Rep. 2015. PMID: 26489474 Free PMC article.
-
Chronic Activation of Tubulin Tyrosination Improves Heart Function.Circ Res. 2024 Oct 11;135(9):910-932. doi: 10.1161/CIRCRESAHA.124.324387. Epub 2024 Sep 16. Circ Res. 2024. PMID: 39279670 Free PMC article.
-
Slowing of contractile kinetics by myosin-binding protein C can be explained by its cooperative binding to the thin filament.J Mol Cell Cardiol. 2016 Jul;96:2-10. doi: 10.1016/j.yjmcc.2015.10.007. Epub 2015 Oct 8. J Mol Cell Cardiol. 2016. PMID: 26454159 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous